S&S On Biotech

To continue listening to thought-provoking podcasts on biotech, pharma, and medtech visit: biobizbuzz.com. Conversations on the science and business of Biotechnology with Andy Smith and Cormac Sheridan.

S&S On Biotech is a business podcast hosted by S&S Ltd., with 31 episodes on record and a Required Pod Score of 81. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

S&S Ltd. hosts S&S On Biotech, a business show with 31 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  S&S On Biotech

  3.9 The slow rise of TCR-T therapy

  Jul 29, 202436 minS0

  <p>When the first chimeric antigen receptor T-cell (CAR-T) therapy was approved in 2017, there was a general expectation that T-cell receptor T-cell (TCR-T) therapies would follow shortly afterwards and would greatly expand the range of addressable antigens. Despite considerable efforts, CAR-T therapies are still limited to haematological cancers expressing extracellular antigens, such as CD19 or B-cell maturation antigen (BCMA). </p><p>Autologous TCR-T therapies can be engineered to target intracellular as well as extracellular peptide antigens presented on the cell surface by human leukocyte antigens (HLAs) and can be more readily used in solid tumors as well as in haematological c...

  ListenShow Notes
• 

  Episode #8

  3.8 Innovation in Myasthenia Gravis: The leap from poison arrows to targeted therapy

  Jul 15, 202429 minS3

  <p>In 1934, Mary Walker, a pioneering Scottish physician, successfully, albeit transiently, treated a myasthenia gravis patient with physostigmine, a traditional remedy for treating poisoning with curare. She had noticed that the signs and symptoms of myasthenia gravis resembled those caused by curare, a preparation of plant alkaloids used to arm poison arrows by some indigenous peoples in Central and South America. Her clinical observations were extraordinarily accurate. At a molecular level, curare, which induces muscle paralysis, acts as a competitive inhibitor of the neurotransmitter acetylcholine by binding the nicotinic acetylcholine receptor and preventing the transmission of an action potential across...

  ListenShow Notes
• 

  S&S On Biotech

  3.7 Melanoma: At the frontier of cancer immunotherapy

  Jul 2, 202432 minS0

  <p>Melanoma has been at the very centre of the cancer immunotherapy revolution over the past decade and a half. The CTLA-4 inhibitor Yervoy (ipilimumab), which gained approval in 2011, was the first agent to demonstrate a survival improvement in a phase 3 trial for metastatic melanoma. It was also the first immune checkpoint inhibitor to gain approval, and it kick-started a whole new era in cancer therapy, based on jamming the cancer’s immunosuppressive signals to enable patients’ T-cells to attack cancer cells. <br/><br/>The first PD-1 inhibitors followed shortly afterwards, and these proved even more active. Combinations proved even more...

  ListenShow Notes
• 

  Episode #6

  3.6 Brain Cancer – The unkindest cancer of all?

  Jun 18, 202430 minS3

  <p>This is a sobering episode that traces the history of the treatment of brain cancer – principally malignant glioma, since it is the most common diagnosis in a thankfully rare oncology indication – and how, unlike many of the indications we have discussed, the treatment options have been limited. The diagnosis of brain cancer often takes too long, partly because headaches and behavioural changes divert patient referrals to other specialities before patients end up at the door of a neurosurgeon after a CT scan. Surgical removal of tumours, chemotherapy and radiation then remained the staple of care for decades. Even the Glia...

  ListenShow Notes
• 

  Episode #5

  3.5 Eyes on the prize: Developing therapies for ophthalmic disease

  Jun 9, 202438 minS3

  <p><br/><br/>Ophthalmology has long been a fruitful area for biotechnology innovation. In highly prevalent conditions associated with ageing, such as age-related macular degeneration, or with chronic disease, such as diabetic macular oedema, vascular endothelial growth factor inhibitors have made important contributions to stabilizing vision over the past two decades. Incremental innovation has steadily improved efficacy while lowering the frequency of injections. And newer targets, such as components of the complement cascade and angiopoietin, are extending the range of therapeutic options available. </p><p> Progress in inherited retinal disease (IRD) has been slower, however. No gene therapy has gained ap...

  ListenShow Notes

Recent guests on S&S On Biotech. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.